Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Official Title

Phase 2 Multicentre Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX -2011 and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer

Summary:

JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.

Trial Description

Primary Outcome:

  • % subjects with overall response (OR)
Secondary Outcome:
  • % subjects with adverse events (AEs)
  • % subjects with serious adverse events (SAEs)
  • % subjects with clinically significant change from baseline in clinical laboratory tests
  • % subjects with anti-drug antibodies (ADA) to treatment
  • % of subjects with neutralizing antibodies (NAb) to treatment
  • % of subjects with clinically significant changes in electrocardiogram (ECG) measurements
  • Area under the serum concentration-time curve (AUC)
  • Maximum measured concentration in serum (Cmax)
  • Time from dosing to maximum measured concentration (tmax)
  • Terminal half-life (t1/2)
  • Total clearance of the analyte in serum (CL)
  • Apparent volume of distribution during specific time points
  • Median duration of response (DOR)
  • Disease control rate (DCR)
  • Landmark progression free survival (PFS)
  • Median PFS
  • Median overall survival (OS)
Vopratelimab is an agonist monoclonal antibody that specifically binds to the Inducible CO-Stimulator of T cells (ICOS) to generate an anti-tumour immune response. This is a Phase 2, open label study to evaluate the safety and efficacy of vopratelimab in combination with ipilimumab in adult subjects with advanced and/or refractory non-small cell lung cancer and urothelial cancer.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society